SUN PHARMA ADVANCED RESEARCH COMPANY LTD.

Sun Pharma Advanced Research Company Ltd (SPARC) announced a change in its directorship. Dr. Rajamannar Thennati will retire from the Board of Directors upon completion of his term at the 21st Annual General Meeting on August 10, 2026. Concurrently, Mr. Anil Raghavan, the current Chief Executive Officer (CEO), has been appointed as the Managing Director and Chief Executive Officer, effective August 11, 2026. This appointment is subject to shareholder approval at the upcoming AGM. Mr. Raghavan is not related to any existing directors and has no disqualifications from SEBI. His profile highlights extensive experience in consulting and a deep interest in pharmaceutical R&D and healthcare delivery.

Sun Pharma Advanced Research Company Ltd (SPARC) has announced its 21st Annual General Meeting (AGM) will be held on Monday, August 10, 2026, at 4:30 PM IST. The meeting will be conducted via Video Conference (VC) or Other Audio-Visual Means (OAVM), adhering to current regulatory guidelines. The Annual Report for FY 2025-26, including the AGM notice, will be electronically distributed to shareholders with registered email addresses. Shareholders are advised to update their contact details with depositories and the company's registrar to ensure timely receipt of the report. Monday, August 03, 2026, has been set as the cut-off date for determining shareholder eligibility to vote and attend the AGM.

Sun Pharma Advanced Research Company Ltd. (SPARC) has announced changes in its Senior Management Team. Ms. Shanta Gupta, Functional Head – Human Resources & Administration, and Dr. Nitin Dharmadhikari, Chief Operating Officer, will retire effective June 30, 2026. Concurrently, Mr. Prasanna Deshmukh has been appointed as the new Functional Head – Human Resources & Administration, effective July 01, 2026. Mr. Deshmukh brings experience from Sun Pharmaceutical Industries Ltd. and prior roles at Marico Ltd. and Crompton Ltd.

Sun Pharma Advanced Research Company Ltd (SPARC) announced the mutual termination of its License Agreement with CMS Bridging DMCC, originally dated November 5, 2019. The termination is effective June 25, 2026. The agreement was for the development and commercialization of multiple products, including XelprosTM, ElepsiaTM, TaclantisTM, PDP-716, and SDN-037, in specific Asian markets. SPARC stated that this termination will have no material impact on its financial position, operations, or other business activities. The disclosure was made in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sun Pharma Advanced Research Company Ltd has announced the closure of its trading window effective Wednesday, July 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct. The trading window will remain shut until 48 hours after the declaration of the company's unaudited financial results for the quarter ended June 30, 2026. The specific date for the board meeting to approve these financial results will be communicated separately.

Shanghvi Finance Private Limited, as an acquirer, along with Persons Acting in Concert (PACs), has made a disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 regarding the acquisition of shares in Sun Pharma Advanced Research Company Limited. Shanghvi Finance Private Limited acquired 3,85,10,000 shares, representing 10.61% of the expanded equity share capital.

Sun Pharma Advanced Research Company Ltd announced that its licensing partner, Ocuvex Therapeutics Inc., received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for PDP-716. The CRL was issued due to inspection findings at the finished product manufacturing facility. The FDA did not raise any other issues with the PDP-716 NDA.

Sun Pharma Advanced Research Company Ltd has allotted 3,85,10,000 warrants to Shanghvi Finance Private Limited at ₹155.80 per warrant on a preferential basis. The company received ₹1,49,99,64,500, equivalent to 25% of the warrant issue price, in accordance with SEBI ICDR Regulations. Each warrant is convertible into one fully paid-up equity share of face value ₹1. The allotment was approved by the Securities Allotment Committee.

Sun Pharma Advanced Research Company Ltd. announced the approval of audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, during its Board of Directors meeting held on May 18, 2026. The statutory auditors have issued an unmodified opinion on these financial results. The meeting commenced at 05:30 P.M. (1ST) and concluded at 07:00 P.M. (1ST).

Sun Pharma Advanced Research Company Ltd has scheduled a Board of Directors meeting on May 18, 2026, to consider and approve the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The trading window for dealing in the company's shares has been closed from April 01, 2026, and will remain closed until 48 hours after the financial results are declared.